Merge Labs grows from Forest Neurotech FRO — ultrasound molecular BCI approach explained
Summary
Merge Labs' technical approach grows directly from Forest Neurotech — a Focused Research Organization dedicated to ultrasound-based neural technology. Forest Neurotech proved the FRO model works for long-horizon BCI R&D, enabling the technical breakthroughs that attracted $252M to commercialize the approach. Merge Labs' non-invasive BCI uses ultrasound to reach deep brain targets without surgery — contrasting with Neuralink's surgical implant and Synchron's endovascular catheter. The molecular approach connects with neurons via biological agents rather than electrodes, targeting the information density limitations of conventional EEG. Forest and Merge Labs continue as sister organizations, with Forest maintaining the FRO research function and Merge Labs handling commercialization.
Why it matters
The FRO model — Forest Neurotech as a nonprofit research organization that produces the science, Merge Labs as the venture-backed commercialization vehicle — is the most capital-efficient structure for deep neurotech research to date. By separating the long-horizon exploratory research (Forest, nonprofit, patient capital) from the commercialization (Merge Labs, venture capital, milestone-driven) the structure avoids the pressure to prematurely commercialize that kills deep tech research programs.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial